Baynes Roy D. 4

What Happened Roy D. Baynes, a director of Travere Therapeutics (TVTX), exercised stock options and immediately sold the resulting shares on June 12, 2026. He exercised 4,500 options at $21.38 per share (total exercise cost $96,210), and sold 4,500 shares in an open-market transaction at $50.00 per share for proceeds of $225,000. The sale was executed under a pre-established 10b5-1 trading plan.

Key Details

• Transaction date: 2026-06-12. Filing date: 2026-06-16 (appears timely under SEC Form 4 rules).
• Exercise: 4,500 option shares acquired at $21.38 each; total cost $96,210. (Footnote F2: option fully vested and exercisable.)
• Sale: 4,500 shares sold at $50.00 each; proceeds $225,000. (Footnote F1: sale pursuant to a 10b5-1 plan adopted Nov 17, 2025.)
• Additional Form 4 line: a derivative disposition for 4,500 shares reported at $0 (reflects option conversion/exercise mechanics shown on the form).
• Shares owned after the transaction: Not disclosed in the provided filing.

Context

• This was an option exercise followed by an immediate open-market sale (a typical "exercise and sell" transaction). Because the sale was made under a 10b5-1 plan, it was pre-arranged and generally viewed as routine rather than an ad-hoc decision based on inside information.
• The filing’s footnotes clarify the options were fully vested and the sale was governed by the trading plan. This is common for directors monetizing vested equity; it does not itself indicate future company performance.